Evidence map›Paper›PMID 31598605›Full record

ArticleArchives of rheumatology2019

Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis.

Nuh Ataş, Özkan Varan, Hakan Babaoğlu, Hasan Satiş, Reyhan Bilici Salman, Abdurrahman Tufan

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nuh AtaşDepartment of Internal Medicine, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey.
Özkan VaranDepartment of Internal Medicine, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey.
Hakan BabaoğluDepartment of Internal Medicine, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey.
Hasan SatişDepartment of Internal Medicine, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey.
Reyhan Bilici SalmanDepartment of Internal Medicine, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey.
Abdurrahman TufanDepartment of Internal Medicine, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey.
Gazi University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although glucocorticoids are the mainstay of treatment in Takayasu arteritis (TA), anti-tumor necrosis factor agents are other treatment options in refractory disease. The onset of TA is generally observed in females of reproductive age. Certolizumab pegol (CZP) lacks a fragment crystallizable region and this gives advantage of minimal transfer through the placenta, which makes CZP a safer option in pregnancy. Although there are case reports and trials about use of infliximab, etanercept, and adalimumab in TA, there are scarce data about use of CZP. In this article, we present three TA cases treated with CZP. While two patients benefited from CZP, one patient was refractory to CZP.

Indexed as

Anti-tumor necrosis factorcertolizumab pegolpregnancyTakayasu arteritis

Identifiers

PMID31598605
PMCPMC6768783
OpenAlexW2971777353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.